BVS (Bioventus) Total Liabilities: $416.3 Mil (As of Mar. 2026)


BVS Bioventus Inc BVS
66 GF Score
Price $9.78
GF Value $6.79
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bioventus Total Liabilities?

Bioventus BVS 66 Total Liabilities is $416.3 Mil as of Mar. 2026. GuruFocus rates BVS with a GF Score™ of 66/100 and a GF Value™ of $6.79 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bioventus's Total Liabilities for the quarter that ended in Mar. 2026 was $416.3 Mil.

Bioventus's quarterly Total Liabilities declined from Sep. 2025 ($494.34 Mil) to Dec. 2025 ($455.11 Mil) and declined from Dec. 2025 ($455.11 Mil) to Mar. 2026 ($416.27 Mil).

Bioventus's annual Total Liabilities declined from Dec. 2023 ($589.79 Mil) to Dec. 2024 ($542.35 Mil) and declined from Dec. 2024 ($542.35 Mil) to Dec. 2025 ($455.11 Mil).

Bioventus Total Liabilities Historical Data

* Premium members only.

The historical data trend for Bioventus's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioventus Total Liabilities Chart

Bioventus Annual Data
Trend Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 692.07 960.43 589.79 542.35 455.11

Bioventus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 505.94 505.49 494.34 455.11 416.27
BVS
66GF Score
Bioventus Inc BVS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioventus Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bioventus's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=160.38+(278.951+15.348
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.433+0+0)
=455.1

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=683.559-228.447
=455.1

Bioventus's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=148.095+(253.326+14.285
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.568+0+0)
=416.3

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=650.539-234.265
=416.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $416.3 Mil mean?
Bioventus (BVS) has a Total Liabilities of $416.3 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bioventus and its competitors.
Is Bioventus' Total Liabilities too high?
Bioventus' current Total Liabilities is $416.3 Mil. Overall, Bioventus has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' Total Liabilities compare to SSII and TCMD?
Bioventus' Total Liabilities of $416.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Bioventus and its competitors. Bioventus's current Total Liabilities is $416.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.79, compared to a current price of $9.78 — trading 44% above its estimated fair value. The current Total Liabilities is $416.3 Mil. Bioventus' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Bioventus (BVS), the current Total Liabilities is $416.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioventus (BVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bioventus stock appears to be overvalued. The current stock price of $9.78 is trading 44% above its estimated GF Value™ of $6.79. GuruFocus considers Bioventus to be Significantly Overvalued.

Key valuation signals for BVS:

  • Total Liabilities: $416.3 Mil
  • GF Value™: $6.79 vs. price of $9.78 (44% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioventus Business Description

Other Exchanges 4B8:Germany
Address 4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
66GF Score

Get the complete analysis for BVS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.78
Price
$6.79
GF Value